Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SRPT

Sarepta Therapeutics Inc

May 14 • 04:00PM ET

132.66

Dollar change +0.96
Percentage change 0.73	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VXF VBK IBB IWP IWF IWR SCHM VHT

Index	-	P/E	1994.89	EPS (ttm)	0.07	Insider Own	5.86%	Shs Outstand	93.73M	Perf Week	-2.48%
Market Cap	12.54B	Forward P/E	13.28	EPS next Y	9.99	Insider Trans	-0.50%	Shs Float	88.98M	Perf Month	12.13%
Income	16.90M	PEG	-	EPS next Q	-0.10	Inst Own	85.56%	Short Float	6.40%	Perf Quarter	6.82%
Sales	1.40B	P/S	8.94	EPS this Y	156.76%	Inst Trans	6.35%	Short Ratio	6.17	Perf Half Y	66.97%
Book/sh	10.17	P/B	13.04	EPS next Y	203.34%	ROA	0.54%	Short Interest	5.69M	Perf Year	10.37%
Cash/sh	14.71	P/C	9.02	EPS next 5Y	-	ROE	2.02%	52W Range	55.25 - 159.89	Perf YTD	37.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.21%	ROI	0.76%	52W High	-17.03%	Beta	0.96
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	32.89%	Gross Margin	85.20%	52W Low	140.11%	ATR (14)	4.99
Dividend Ex-Date	-	Current Ratio	4.05	EPS Y/Y TTM	101.12%	Oper. Margin	-6.76%	RSI (14)	60.54	Volatility	3.43% 4.10%
Employees	1314	Debt/Eq	1.44	Sales Y/Y TTM	43.83%	Profit Margin	1.20%	Recom	1.38	Target Price	168.30
Option/Short	Yes / Yes	LT Debt/Eq	1.33	EPS Q/Q	106.22%	Payout	-	Rel Volume	1.31	Prev Close	131.70
Sales Surprise	8.94%	EPS Surprise	2768.22%	Sales Q/Q	63.10%	Earnings	May 01 AMC	Avg Volume	922.49K	Price	132.66
SMA20	4.79%	SMA50	5.65%	SMA200	17.33%	Trades		Volume	1,205,845	Change	0.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$170
Dec-13-23	Resumed	Citigroup	Buy	$113
Dec-12-23	Initiated	Deutsche Bank	Buy	$109
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$166 → $40
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line	$139
Apr-26-23	Initiated	SMBC Nikko	Outperform	$185
Apr-04-23	Initiated	Citigroup	Buy	$179
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$141 → $187
Dec-22-22	Reiterated	BTIG Research	Buy	$125 → $160
Dec-16-22	Upgrade	UBS	Neutral → Buy	$100 → $158
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$140
Jan-05-22	Reiterated	Needham	Buy	$157 → $150
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform	$125
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight	$130
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral	$92 → $87
Jun-15-21	Initiated	BTIG Research	Buy	$110

Show Previous Ratings

May-14-24 07:30AM	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180 (MT Newswires)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
May-03-24 10:07AM	Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health (Business Wire)
May-02-24 03:42PM	Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says (MT Newswires)
11:30AM	UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating (MT Newswires)
11:13AM	Loading…
11:13AM	Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
11:08AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:52AM	Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating (MT Newswires)
06:01AM	Q1 2024 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:32AM	Sarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-01-24 08:55PM	SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:30PM	Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:30PM	Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript (Motley Fool)
05:20PM	Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates (Zacks)
05:06PM	Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours (MT Newswires)
04:19PM	Loading…
04:19PM	Sarepta Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments (Business Wire)
09:15AM	1 Top Growth Stock to Buy and Hold for 10 Years (Motley Fool)
Apr-30-24 06:38PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:28AM	Why Sarepta (SRPT) Might Surprise This Earnings Season (Zacks)
Apr-29-24 03:20PM	Sarepta Therapeutics Stock Shows Improved Technical Strength (Investor's Business Daily)
Apr-24-24 08:30AM	Sarepta Therapeutics to Announce First Quarter 2024 Financial Results (Business Wire) +6.09%
Apr-13-24 09:39PM	10 Unstoppable Stocks That Will Make You Richer (Insider Monkey)
Apr-08-24 04:13PM	Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst (Investor's Business Daily)
Apr-06-24 08:45AM	2 Biotech Stocks to Buy Hand Over Fist in April (Motley Fool)
Apr-02-24 07:04AM	Outperforming ETF manager names a potential 50-bagger in the stock market (MarketWatch)
Mar-29-24 04:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:30AM	Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-26-24 07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
Mar-25-24 10:00AM	A Comprehensive Look at Sarepta's Growth and Innovation (GuruFocus.com)
08:50AM	Loading…
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 03:53PM	Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-13-24 08:00AM	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? (Motley Fool)
Mar-12-24 01:18AM	Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Mar-11-24 09:03AM	Billionaire Ray Dalio and Insiders Love These 10 Stocks (Insider Monkey)
Mar-06-24 11:54PM	Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Mar-04-24 09:47AM	Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst (Motley Fool)
08:30AM	Sarepta Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Mar-02-24 12:05AM	Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight (GuruFocus.com)
Feb-29-24 06:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.98%
12:35PM	Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
10:52AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
12:00AM	Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript (Motley Fool)
Feb-28-24 06:00PM	Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:23PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments (Business Wire)
07:15AM	Is It Too Late to Buy Sarepta Therapeutics Stock? (Motley Fool)
Feb-27-24 08:48AM	Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) (Zacks)
Feb-21-24 11:24AM	Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates? (Zacks)
08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-20-24 10:00AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-19-24 03:26AM	Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last? (Zacks)
Feb-16-24 11:23AM	Why Sarepta Therapeutics Stock Is Soaring Today (Motley Fool) +7.78%
11:22AM	Prospects Look Better for Sarepta Gene Therapy, Sending the Stock Up Again (Barrons.com)
08:46AM	UPDATE 3-US FDA to review Sarepta's Duchenne gene therapy for traditional approval (Reuters)
07:41AM	CORRECTED-UPDATE 1-US FDA to review Sarepta's Duchenne gene therapy for traditional approval (Reuters)
07:22AM	U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy (Reuters)
07:00AM	Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication (Business Wire)
Feb-15-24 07:45AM	2 Magnificent Growth Stocks to Buy With $500 (Motley Fool)
Feb-11-24 01:45AM	1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? (Motley Fool)
Jan-31-24 06:29PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-24 07:37AM	UPDATE 3-Sarepta's new Duchenne drug outperforms bestseller Exondys in trial (Reuters)
07:12AM	REFILE-Sarepta says its experimental Duchenne drug more effective than older medicine (Reuters)
07:00AM	Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 (Business Wire)
06:50AM	Sarepta data show new Duchenne drugs potency, but highlight side effects (BioPharma Dive)
Jan-26-24 05:15AM	Got $3,000? 3 Growth Stocks to Double Up On Right Now (Motley Fool)
Jan-25-24 09:45AM	Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool)
Jan-22-24 05:47PM	Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today (Motley Fool)
09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet (Zacks)
09:38AM	Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates (Insider Monkey)
Jan-16-24 03:57PM	Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market (InvestorPlace)
09:02AM	Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 (Business Wire)
Jan-10-24 11:43AM	Sarepta Rebounded. Its Gene Therapy Is Back on Course. (Barrons.com)
06:17AM	Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains? (Zacks)
Jan-09-24 11:22AM	Why Is Sarepta Therapeutics (SRPT) Stock Up Today? (InvestorPlace) +16.72%
10:52AM	Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results (Zacks)
07:15AM	2 Growth Stocks That Could Make You Richer in 2024 and Beyond (Motley Fool)
Jan-08-24 11:55AM	Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue (Business Wire) +5.41%
Jan-04-24 09:55AM	Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade (Zacks)
Jan-02-24 08:30AM	Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-29-23 06:27PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:44AM	Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Dec-28-23 10:07AM	3 Things About Sarepta Therapeutics Every Smart Investor Knows (Motley Fool)
Dec-27-23 06:26PM	15 Best Fast Growth Stocks to Buy Now (Insider Monkey)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
Dec-22-23 02:49PM	Sarepta Therapeutics Seen Expanding Duchenne Treatment Label (Barrons.com)
10:15AM	Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? (Motley Fool)
08:00AM	Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status (Business Wire)
06:33AM	Sarepta tests FDA flexibility with bid to expand Duchenne gene therapys approval (BioPharma Dive)
Dec-17-23 09:45AM	1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond (Motley Fool)
Dec-15-23 09:55AM	Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? (Zacks)
Dec-12-23 12:43PM	10 Beaten Down Stocks Billionaires Are Crazy About (Insider Monkey)
Dec-09-23 07:00AM	Could Sarepta Therapeutics Stock Help You Become a Millionaire? (Motley Fool)
Dec-01-23 11:31AM	Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-30-23 06:34PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet (Zacks)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:26AM	13 Stocks Insiders are Buying Now (Insider Monkey)
Nov-18-23 06:49AM	3 Monster Stocks in the Making (Motley Fool)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murray Dallan	Chief Customer Officer	May 02 '24	Sale	140.00	3,635	508,900	18,125	May 06 08:09 PM
Boor Kathryn Jean	Director	Mar 11 '24	Sale	122.93	761	93,550	7,516	Mar 11 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Option Exercise	13.90	15,000	208,500	37,840	Mar 11 08:02 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Sale	123.25	15,000	1,848,795	22,840	Mar 11 08:02 PM
Mayo Stephen	Director	Mar 05 '24	Sale	122.96	3,135	385,480	6,621	Mar 06 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Mar 01 '24	Sale	128.84	2,000	257,676	26,836	Mar 05 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Mar 01 '24	Sale	125.34	2,000	250,680	31,827	Mar 05 08:00 PM
Estepan Ian Michael	Chief Financial Officer	Mar 01 '24	Sale	128.30	1,200	153,960	39,114	Mar 05 08:00 PM
BEHRENS M KATHLEEN	Director	Nov 03 '23	Option Exercise	29.03	15,000	435,450	174,993	Nov 06 08:00 AM
Barry Richard	Director	Nov 03 '23	Buy	78.81	50,000	3,940,500	140,000	Nov 06 08:00 AM
INGRAM DOUGLAS S	President & CEO	Nov 03 '23	Buy	79.36	25,225	2,001,800	390,307	Nov 06 08:00 AM
Chambers Michael Andrew	Director	Aug 14 '23	Buy	109.47	9,979	1,092,429	246,996	Aug 15 08:00 AM
Chambers Michael Andrew	Director	Aug 11 '23	Buy	108.05	23,686	2,559,272	237,017	Aug 14 08:00 AM
Chambers Michael Andrew	Director	Aug 10 '23	Buy	106.15	34,867	3,701,067	213,331	Aug 11 07:40 AM
Wigzell Hans Lennart Rudolf	Director	Aug 04 '23	Option Exercise	29.03	15,000	435,450	35,994	Aug 08 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 04 '23	Sale	106.72	15,000	1,600,800	20,994	Aug 08 08:00 PM

Open in Screener

ALLO

Allogene Therapeutics Inc

May 14 • 04:00PM ET

2.96

Dollar change +0.06
Percentage change 2.07	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

ALLO Allogene Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWM VB VBK IWN IBB LABU VHT VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	34.30%	Shs Outstand	170.72M	Perf Week	1.72%
Market Cap	505.33M	Forward P/E	-	EPS next Y	-1.61	Insider Trans	-0.03%	Shs Float	112.16M	Perf Month	-16.62%
Income	-290.08M	PEG	-	EPS next Q	-0.37	Inst Own	59.86%	Short Float	30.20%	Perf Quarter	-35.79%
Sales	0.13M	P/S	3887.16	EPS this Y	24.69%	Inst Trans	5.02%	Short Ratio	16.15	Perf Half Y	18.40%
Book/sh	2.71	P/B	1.09	EPS next Y	-2.05%	ROA	-43.52%	Short Interest	33.87M	Perf Year	-51.40%
Cash/sh	2.25	P/C	1.31	EPS next 5Y	1.00%	ROE	-55.06%	52W Range	2.23 - 6.89	Perf YTD	-7.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.18%	ROI	-52.72%	52W High	-57.04%	Beta	0.89
Dividend TTM	-	Quick Ratio	12.80	Sales past 5Y	-27.79%	Gross Margin	-7505.91%	52W Low	32.74%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	12.80	EPS Y/Y TTM	26.64%	Oper. Margin	-219123.85%	RSI (14)	39.69	Volatility	10.97% 7.75%
Employees	-	Debt/Eq	0.21	Sales Y/Y TTM	-24.70%	Profit Margin	-223140.00%	Recom	1.65	Target Price	11.68
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	43.72%	Payout	-	Rel Volume	4.04	Prev Close	2.90
Sales Surprise	96.43%	EPS Surprise	7.23%	Sales Q/Q	-57.69%	Earnings	May 13 AMC	Avg Volume	2.10M	Price	2.96
SMA20	-3.35%	SMA50	-24.38%	SMA200	-17.78%	Trades		Volume	8,470,537	Change	2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy	$53
May-20-21	Upgrade	Truist	Hold → Buy	$34 → $41
May-14-21	Initiated	B. Riley Securities	Buy	$52

Show Previous Ratings

May-14-24 12:56PM	Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag (Zacks)
09:14AM	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating (MT Newswires)
08:21AM	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating (MT Newswires)
03:06AM	Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.07%
05:36PM	Loading…
05:36PM	Allogene Therapeutics Prices $110 Million Offering (MT Newswires)
05:10PM	Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock (GlobeNewswire)
04:17PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:14PM	Allogene Therapeutics Q1 Loss Narrows, Revenue Declines (MT Newswires)
04:01PM	Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:30AM	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update (GlobeNewswire)
Apr-26-24 10:32AM	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development (MT Newswires)
08:30AM	Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma (GlobeNewswire)
Apr-24-24 10:01AM	Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -9.79%
02:45PM	Loading…
Apr-11-24 02:45PM	3 Meme Stocks to Sell and Replace With Meme Coins (InvestorPlace)
Apr-09-24 08:30AM	Allogene Therapeutics Announces Q2 Investor Conference Participation (GlobeNewswire)
Apr-08-24 08:46AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Mar-16-24 04:35PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 09:32AM	Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
07:04AM	Q4 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.89%
05:34PM	Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ... (GuruFocus.com)
05:15PM	Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-13-24 12:15PM	Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology (Zacks)
Mar-12-24 08:50AM	Allogene taps Arbor in pursuit of off-the-shelf CAR-T therapies for autoimmune disease (BioPharma Dive)
08:30AM	Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease (GlobeNewswire)
Mar-05-24 09:55AM	Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:30AM	Loading…
08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update (GlobeNewswire)
Feb-28-24 08:30AM	Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-16-24 08:30AM	Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia (GlobeNewswire)
Jan-16-24 04:05PM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-24 08:34AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Jan-05-24 12:52PM	Allogene (ALLO) Down 20% on Strategic Changes in Pipeline (Zacks) -14.01%
08:25AM	UPDATE 2-Allogene to cut 22% of its workforce (Reuters)
08:13AM	Allogene to cut 22% of its workforce (Reuters)
Jan-04-24 04:15PM	Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
04:05PM	Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
11:05AM	Allogene to shift strategy in bid to reposition CAR-T (BioPharma Dive)
Jan-03-24 04:05PM	Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.01%
Dec-09-23 12:00PM	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Dec-01-23 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conference (GlobeNewswire) +7.23%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-10-23 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-03-23 12:15PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript (Insider Monkey) +17.85%
12:00PM	Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak and Dagger Technologies at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
12:00PM	Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
10:15AM	Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-02-23 07:33PM	Allogene Therapeutics Inc (ALLO) Reports Q3 2023 Financial Results (GuruFocus.com)
04:12PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
09:00AM	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Oct-30-23 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +9.09%
Oct-26-23 08:30AM	Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-16-23 09:26AM	The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics (Zacks)
08:30AM	Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer (GlobeNewswire)
Sep-27-23 09:09AM	Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-25-23 08:45AM	JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment (Investing.com)
Sep-05-23 08:30AM	Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-14-23 08:30AM	Allogene Therapeutics Appoints Earl Douglas as General Counsel (GlobeNewswire)
Aug-03-23 11:20AM	Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss (Zacks) +9.59%
Aug-02-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Allogene Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks)
Jul-26-23 08:30AM	Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jun-15-23 09:30AM	Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
Jun-14-23 08:00AM	Allogene Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -12.54%
Jun-09-23 06:25PM	Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-03-23 09:00AM	Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-02-23 11:31AM	Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound? (Zacks) +5.45%
May-31-23 12:02PM	Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal (Zacks)
10:46AM	J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH (Zacks)
May-29-23 07:48AM	AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal (Zacks)
May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
09:55AM	Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High? (Zacks)
08:23AM	PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study (Zacks)
May-25-23 03:16PM	Immutep (IMMP) Up on Initial Data From Lung Cancer Study (Zacks)
May-24-23 11:37AM	Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data (Zacks) -5.95%
08:30AM	Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-22-23 08:16AM	We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-19-23 11:16AM	PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study (Zacks)
10:24AM	AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease (Zacks)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace)
12:45PM	MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study (Zacks)
11:15AM	Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing (Zacks)
May-17-23 02:19PM	Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag (Zacks)
11:21AM	PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up (Zacks)
11:13AM	Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag (Zacks)
May-16-23 09:31AM	Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases (Zacks) -9.05%
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
10:04AM	Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why (Zacks)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Jan 30 '24	Buy	3.60	190	683	819,590	Mar 06 09:52 PM
MESSEMER DEBORAH M.	Director	Dec 18 '23	Sale	2.70	18,640	50,317	62,456	Dec 20 04:26 PM
Mayo Stephen	Director	Aug 07 '23	Sale	4.29	10,000	42,855	25,328	Aug 09 04:07 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SRPT

Sarepta Therapeutics Inc

ALLO

Allogene Therapeutics Inc

Upgrade your FINVIZ experience